...
首页> 外文期刊>Biological psychiatry >Genetic inactivation of dopamine D1 but not D2 receptors inhibits L-DOPA-induced dyskinesia and histone activation.
【24h】

Genetic inactivation of dopamine D1 but not D2 receptors inhibits L-DOPA-induced dyskinesia and histone activation.

机译:多巴胺D1受体而非D2受体的遗传失活抑制了L-DOPA诱导的运动障碍和组蛋白活化。

获取原文
获取原文并翻译 | 示例

摘要

BACKGROUND: Pharmacologic studies have implicated dopamine D1-like receptors in the development of dopamine precursor molecule 3,4-dihydroxyphenyl-L-alanine (L-DOPA)-induced dyskinesias and associated molecular changes in hemiparkinsonian mice. However, pharmacologic agents for D1 or D2 receptors also recognize other receptor family members. Genetic inactivation of the dopamine D1 or D2 receptor was used to define the involvement of these receptor subtypes. METHODS: During a 3-week period of daily L-DOPA treatment (25 mg/kg), mice were examined for development of contralateral turning behavior and dyskinesias. L-DOPA-induced changes in expression of signaling molecules and other proteins in the lesioned striatum were examined immunohistochemically. RESULTS: Chronic L-DOPA treatment gradually induced rotational behavior and dyskinesia in wildtype hemiparkinsonian mice. Dyskinetic symptoms were associated with increased FosB and dynorphin expression, phosphorylation of extracellular signal-regulated kinase, and phosphoacetylation of histone 3 (H3) in the lesioned striatum. These molecular changes were restricted to striatal areas with complete dopaminergic denervation and occurred only in dynorphin-containing neurons of the direct pathway. D1 receptor inactivation abolished L-DOPA-induced dyskinesias and associated molecular changes. Inactivation of the D2 receptor had no significant effect on the behavioral or molecular response to chronic L-DOPA. CONCLUSIONS: Our results demonstrate that the dopamine D1 receptor is critical for the development of L-DOPA-induced dyskinesias in mice and in the underlying molecular changes in the denervated striatum and that the D2 receptor has little or no involvement. In addition, we demonstrate that H3 phosphoacetylation is blocked by D1 receptor inactivation, suggesting that inhibitors of H3 acetylation and/or phosphorylation may be useful in preventing or reversing dyskinesia.
机译:背景:药理学研究牵涉多巴胺D1样受体参与多巴胺前体分子3,4-二羟基苯基-L-丙氨酸(L-DOPA)引起的运动障碍和相关的半帕金森氏小鼠分子变化。但是,D1或D2受体的药物也可以识别其他受体家族成员。多巴胺D1或D2受体的遗传失活被用来定义这些受体亚型的参与。方法:在每日L-DOPA治疗(3 mg / kg)的3周内,检查小鼠对侧转弯行为和运动障碍的发展。免疫组织化学检查了L-DOPA诱导的受损纹状体中信号分子和其他蛋白质表达的变化。结果:慢性左旋多巴治疗逐渐诱导了野生型半帕金森病小鼠的旋转行为和运动障碍。运动障碍症状与受损纹状体中FosB和强啡肽表达增加,细胞外信号调节激酶的磷酸化以及组蛋白3(H3)的磷酸乙酰化有关。这些分子变化仅限于完全多巴胺能神经支配的纹状体区域,仅发生在含有强啡肽的直接途径神经元中。 D1受体失活消除了L-DOPA引起的运动障碍和相关的分子变化。 D2受体的失活对慢性L-DOPA的行为或分子反应无明显影响。结论:我们的结果表明,多巴胺D1受体对于小鼠L-DOPA诱导的运动障碍的发展以及神经支配纹状体中潜在的分子变化至关重要,并且D2受体几乎没有参与。此外,我们证明H3磷酸乙酰化被D1受体失活所阻止,这表明H3乙酰化和/或磷酸化的抑制剂可能对预防或逆转运动障碍有用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号